What is Penumbra?
Penumbra, Inc. is a global medical device company dedicated to the design, development, manufacturing, and marketing of innovative neurovascular and peripheral vascular devices. Headquartered in Alameda, California, the company operates internationally, serving markets across the United States, Europe, Canada, Australia, and Japan. Penumbra's product portfolio includes advanced neurovascular access systems, such as the Neuron, Neuron MAX, and Velocity brands, designed for intracranial therapies. Additionally, their aspiration-based thrombectomy systems, including the Penumbra System and the 3D revascularization device, are critical in treating conditions like stroke. Founded in 2004, Penumbra has established itself as a key innovator in interventional therapies.
How much funding has Penumbra raised?
Penumbra has raised a total of $120M across 1 funding round:
Stock Offering
$120M
Stock Issuance/Offering (2015): $120M, investors not publicly disclosed
What's next for Penumbra?
With a significant enterprise-level funding history culminating in $120M, Penumbra is strategically positioned for continued advancement in the highly competitive medical device industry. The recent major strategic investment of $120M signals strong investor confidence and provides the necessary capital to accelerate product development, expand manufacturing capabilities, and broaden market penetration. Future growth is likely to be driven by further innovation in minimally invasive neurovascular and peripheral vascular interventions, potentially including expansion into new therapeutic areas or geographic markets. The company's focus on addressing critical unmet needs in stroke and other vascular conditions suggests a trajectory of sustained development and market leadership.
See full Penumbra company page
